Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01320696 · ClinicalTrials.gov registry record · Phase 1
Reverse Genetic H9N2 Influenza Vaccine Study in Adults
A Phase 1 study of Influenza, sponsored by Alachua Government Services.
- Completed
- Registry status
- Phase 1
- Development phase
- 353
- Enrollment target
- 5
- Study locations
NCT01320696 is a Phase 1 study of Influenza that has completed, run by Alachua Government Services. The registered enrollment target is 353 participants, below the 36,802-participant average among 156 other Influenza trials with a reported enrollment target (99% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT01320696, a Phase 1 study of Influenza, has completed, sponsored by Alachua Government Services.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 353 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of the study is to identify the optimal dose level of a reverse genetic (RG) reassortant H9N2 pandemic influenza vaccine for further product development.
Conditions Studied
Interventions
- BIOLOGICAL Reverse Genetic (RG) reassortant A/H9N2 influenza vaccine
Study Locations (5)
Alabama
- Accelovance - Huntsville
Florida
- Accelovance - Melbourne
Illinois
- Accelovance - Peoria
Indiana
- Accelovance - South Bend
Maryland
- Accelovance - Rockville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 353 participants |
| Start Date | 2011-03 |
| Est. Completion | 2012-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01320696
The ClinicalTrials.gov registry entry for NCT01320696 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 353 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 36,802-participant average among 156 other Influenza trials with a reported enrollment target (99% lower). The listed sponsor is Alachua Government Services, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Influenza appearing as the primary indexed condition, and to 1 intervention - of which Reverse Genetic (RG) reassortant A/H9N2 influenza vaccine is the first listed.
NCT01320696 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Alabama, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT01320696 about?
NCT01320696 is a clinical study titled "Reverse Genetic H9N2 Influenza Vaccine Study in Adults". The purpose of the study is to identify the optimal dose level of a reverse genetic (RG) reassortant H9N2 pandemic influenza vaccine for further product development.
What is the current status of trial NCT01320696?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 353 participants. The study started on 2011-03. Estimated completion is 2012-05.
What conditions does trial NCT01320696 study?
This clinical trial studies the following conditions: Influenza.
What interventions are being tested in trial NCT01320696?
The interventions under investigation include: Reverse Genetic (RG) reassortant A/H9N2 influenza vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT01320696?
This trial is sponsored by Alachua Government Services, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01320696 being conducted?
This trial has 5 study locations across Alabama, Florida, Illinois, Indiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Influenza
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
pH1N1 Blinded Challenge Study
RECRUITING · Phase 1
-
A/Texas Flu Challenge
RECRUITING · Phase 1
-
First-in-Human Study of VNT-101: Safety, Tolerability, and Pharmacokinetics
RECRUITING · Phase 1
-
Influenza Human Challenge Model
RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults
ACTIVE NOT RECRUITING · Phase 1
-
Pilot Influenza Challenge Study
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.